Heyan Bio Completes Nearly RMB 100 Million Series A Financing Led by LRI Jiangyuan Investment and Lanshi Capital

VCBeat has learned that Shanghai Huiyueyan Biotechnology Co., Ltd. recently completed an angel financing round of nearly RMB 100 million, jointly invested by LRI Jiangyuan Investment and Rockbleu Capital, with HAOYUE CAPITAL serving as the exclusive financial advisor for this round.

Shanghai Huiyueyan Biotechnology Co., Ltd. was established in 2023 and is aAn Innovative Biomaterials Company Based on Technology Platforms Including Biodegradable Polymer Materials, Microsphere Preparation Technology, and Cross-linking Process Technology. The company's R&D team possesses over 20 years of experience in the field of polymer materials, continuously innovates based on its core technology platform, and has a proven track record of successfully taking products from research and development to commercialization.

LRI Jiangyuan InvestmentHuiyueyan has made in-depth strategic investments in anti-aging and regenerative products, establishing a comprehensive platform for medical-grade microspheres, biodegradable materials, and controlled-release technologies. The company’s founder and core team boast over 20 years of combined experience in scientific research and industry, and are successful serial entrepreneurs who have built a leading domestic platform for material technology innovation. We are highly optimistic about the differentiated advantages of Huiyueyan’s product pipeline and look forward to the company further unlocking its innovative potential and establishing a stronghold in the aesthetic medicine sector.

Mr. Yang Zhenjun, Managing Partner of HAOYUE CAPITALStatement: We are honored to have assisted Huiyeyan in completing this round of financing. Against the backdrop of the booming “beauty economy,” the medical aesthetics sector holds immense potential and remains immune to volume-based procurement (VBP). Leveraging its team’s extensive R&D experience in high-end interventional implantable medical consumables, Huiyeyan has established a high-barrier platform for the commercialization of biodegradable polymer materials, positioning itself as a platform-oriented medical aesthetics enterprise driven by technological innovation, regulatory compliance, and continuous product iteration. We look forward to Huiyeyan fully leveraging its technological and team advantages amid an increasingly stringent regulatory environment for medical aesthetics, thereby becoming a leading value creator in the field of medical aesthetic products.